糖尿病中在ACEI/ARB基础上联用降压药比较
该观察性多中心队列研究纳入21,897例糖尿病患者,比较在ACEI/ARB基础上联用β受体阻滞剂、二氢吡啶类钙通道阻滞剂、袢利尿剂或噻嗪类利尿剂对肾脏复合终点的影响。结果显示,与噻嗪类利尿剂相比,钙通道阻滞剂与较低的重大肾脏事件风险相关,且心血管事件风险相似。
要点
- 在ACEI/ARB基础上联用钙通道阻滞剂,较噻嗪类利尿剂肾脏事件风险更低。
- 钙通道阻滞剂与噻嗪类利尿剂的心血管事件风险相似。
- 袢利尿剂较噻嗪类利尿剂肾脏事件、死亡和心血管事件风险更高。
核心结论
- 与噻嗪类利尿剂相比,钙通道阻滞剂与较低的重大肾脏事件风险相关,且心血管事件风险相似。
研究设计与样本
- 观察性、多中心队列研究,纳入21,897例糖尿病患者,比较在ACEI/ARB基础上联用β受体阻滞剂、二氢吡啶类钙通道阻滞剂、袢利尿剂或噻嗪类利尿剂。
- 采用倾向评分加权的Cox比例风险模型,分析重大肾脏事件、心血管事件和死亡的风险。
主要发现
- 随访最长5年,发生重大肾脏事件4707例、死亡1498例、心血管事件818例。
- 与噻嗪类利尿剂相比,β受体阻滞剂、钙通道阻滞剂和袢利尿剂的重大肾脏事件风险比分别为0.81(95%CI 0.74-0.89)、0.67(95%CI 0.58-0.78)和1.19(95%CI 1.00-1.41)。
- 与噻嗪类利尿剂相比,β受体阻滞剂、钙通道阻滞剂和袢利尿剂的死亡风险比分别为1.19(95%CI 0.97-1.44)、0.73(95%CI 0.52-1.03)和1.67(95%CI 1.31-2.13)。
- 与噻嗪类利尿剂相比,β受体阻滞剂、钙通道阻滞剂和袢利尿剂的心血管事件风险比分别为1.65(95%CI 1.39-1.96)、1.05(95%CI 0.80-1.39)和1.55(95%CI 1.05-2.27)。
临床怎么用
- 对于糖尿病合并高血压且已使用ACEI/ARB的患者,选择联用钙通道阻滞剂可能较噻嗪类利尿剂更有利于降低重大肾脏事件风险。
- 联用袢利尿剂时需警惕较高的肾脏事件、死亡和心血管事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In individuals with diabetes, the comparative effectiveness of add-on antihypertensive medications added to an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on the risk of significant kidney events is unknown. DESIGN, SETTING PARTICIPANTS, & MEASUREMENTS: We used an observational, multicenter cohort of 21,897 individuals with diabetes to compare individuals who added β-blockers, dihydropyridine calcium channel blockers, loop diuretics, or thiazide diuretics to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. We examined the hazard of significant kidney events, cardiovascular events, and death using Cox proportional hazard models with propensity score weighting. The composite significant kidney event end point was defined as the first occurrence of a ≥30% decline in eGFR to an eGFR<60 ml/min per 1.73 m2, initiation of dialysis, or kidney transplant. The composite cardiovascular event end point was defined as the first occurrence of hospitalization for acute myocardial infarction, acute coronary syndrome, stroke, or congestive heart failure; coronary artery bypass grafting; or percutaneous coronary intervention, and it was only examined in those free of cardiovascular disease at baseline. RESULTS: Over a maximum of 5 years, there were 4707 significant kidney events, 1498 deaths, and 818 cardiovascular events. Compared with thiazide diuretics, hazard ratios for significant kidney events for β-blockers, calcium channel blockers, and loop diuretics were 0.81 (95% confidence interval, 0.74 to 0.89), 0.67 (95% confidence interval, 0.58 to 0.78), and 1.19 (95% confidence interval, 1.00 to 1.41), respectively. Compared with thiazide diuretics, hazard ratios of mortality for β-blockers, calcium channel blockers, and loop diuretics were 1.19 (95% confidence interval, 0.97 to 1.44), 0.73 (95% confidence interval, 0.52 to 1.03), and 1.67 (95% confidence interval, 1.31 to 2.13), respectively. Compared with thiazide diuretics, hazard ratios of cardiovascular events for β-blockers, calcium channel blockers, and loop diuretics compared with thiazide diuretics were 1.65 (95% confidence interval, 1.39 to 1.96), 1.05 (95% confidence interval, 0.80 to 1.39), and 1.55 (95% confidence interval, 1.05 to 2.27), respectively. CONCLUSIONS: Compared with thiazide diuretics, calcium channel blockers were associated with a lower risk of significant kidney events and a similar risk of cardiovascular events.
引用
- Schroeder EB, Chonchol M, Shetterly SM, et al. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study. Clin J Am Soc Nephrol. 2018. PMID: 29572286. doi:10.2215/CJN.09510817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。